Neuroplastigen Therapies
for Pain & Headache
healing the root of chronic pain
Using patented ML drug discovery tools invented by our founders at Harvard Medical School, we’re advancing FDA-approved medicines inspired by psychedelic cacti to alleviate chronic pain
Our Focus
-
![]()
-
![]()
Clinical Candidate Selection
ButtonMost novel investigational new drugs fail clinical trials, in large part due to poorly-predictive animal models. We're using the Blackbox One drug development platform to derisk clinical candidate selection of psychedelic NCEs. Upon completion, our rodent behavioral atlas will automatically detect drug-induced behavioral effects including head twitch response (HTR), anxiety, amphetamine-like hyperlocomotion, somnolence/sedation, pain and analgesia, all from a single group of once-dosed rats.
-
![]()
-
![]()
Central Sensitization
ButtonOur scientific team trained under world renowned Harvard neuroscientist, Clifford Woolf, MD, PhD, perhaps best known for his seminal work describing central sensitization of pain. We are exploring which psychedelic assisted therapeutic modalities and molecules are best suited for remapping the sensitized brain circuits that keep patients in chronic pain.
-
![]()
Addressing Childhood Adversity
ButtonOur CEO, Kaitlin Roberson, is a child advocate and former non-profit director whose professional focus, and Harvard graduate training, is optimizing human development through attention to adverse experiences of childhood that often cause hardship later in life.
-
![]()
